Herpesvirus entry mediator (HVEM) – B- and T-lymphocyte attenuator (BTLA) inhibitory checkpoint pathway (HVEM-BTLA pathway)

The Herpesvirus entry mediator (HVEM) – B- and T-lymphocyte attenuator (BTLA) inhibitory checkpoint pathway is a critical regulatory axis in the immune system that modulates T-cell activation and homeostasis (UniProt Q92956, P0C1P6). HVEM, a member of the tumor necrosis factor receptor superfamily (TNFRSF14), interacts with BTLA, an immunoglobulin superfamily member, to deliver a potent coinhibitory signal to lymphocytes (PubMed: 31435046). This interaction is unique as it bridges two different structural families of proteins. In the context of oncology, many tumors overexpress HVEM or exploit the BTLA-HVEM interaction to evade immune surveillance by inducing T-cell exhaustion. Conversely, mutations in TNFRSF14 are frequently observed in follicular lymphomas, leading to altered immune signaling and tumor progression (PubMed: 21804538). Therapeutic strategies currently focus on developing monoclonal antibodies, such as tifcemalimab, that block this interaction to restore T-cell mediated anti-tumor activity (PubMed: 35859114). Beyond cancer, this pathway is also investigated for its role in autoimmune diseases and chronic infections where immune regulation is dysfunctional. The complexity of the pathway is further increased by HVEM's ability to bind other ligands like LIGHT and CD160, which can provide costimulatory or coinhibitory signals depending on the context.

Other names

TNFRSF14-BTLA axisCD270-CD272 pathwayLIGHT-HVEM-BTLA signaling complexHVEM-BTLA checkpoint

Monoclonal antibodies target BTLA or HVEM to block their interaction, preventing the transmission of inhibitory signals to T-cells and enhancing anti-tumor immunity.